10-Q: NVE Corp Q3 Earnings Surge 11% on Strong Sales

NVE Corporation reported an 11% increase in net income for the third quarter of fiscal 2026, driven by robust product sales and contract research and development revenue, despite a lower gross margin.

Summary

• Net income for the third quarter of fiscal 2026 increased 11% to $3.38 million ($0.70 per diluted share) compared to $3.05 million ($0.63 per diluted share) in the prior-year quarter.
• Total revenue for the third quarter of fiscal 2026 rose 23% to $6.22 million, with product sales up 16% and contract research and development revenue surging 335%.
• For the first nine months of fiscal 2026, net income decreased 8% to $10.27 million ($2.12 per diluted share) from $11.17 million ($2.31 per diluted share) in the prior-year period.
• Nine-month total revenue saw a modest 0.4% increase to $18.68 million, driven by product sales growth but partially offset by an 8% decline in contract research and development revenue.
• Gross margin percentage decreased to 79% for both the quarter and nine-month periods, down from 84% and 85% respectively, due to a less profitable product mix and increased distributor sales.
• Total expenses decreased 12% for the quarter and 13% for the nine months, primarily due to reduced research and development and selling, general, and administrative expenses.
• Cash and cash equivalents decreased by $4.63 million to $3.41 million as of December 31, 2025, primarily due to dividend payments and fixed asset purchases, partially offset by strong operating cash flow.
• The company declared a cash dividend of $1.00 per share for the quarter, maintaining the same payout as the prior year.

Sentiment

Score: 7

Explanation: The company reported strong quarterly revenue and net income growth, driven by product sales and R&D contracts, and effectively managed expenses. However, the nine-month net income declined, and gross margins compressed. The extension of a key customer agreement and favorable tax outlook are positive, but new regulatory risks and a decrease in cash balance warrant a balanced view.

Positives

• Quarterly net income increased 11% year-over-year to $3.38 million.
• Total quarterly revenue increased 23% year-over-year to $6.22 million, driven by strong product sales (+16%) and a significant increase in contract research and development revenue (+335%).
• Total expenses decreased 12% for the quarter and 13% for the nine months, reflecting efficiencies in research and development and selling, general, and administrative expenses.
• Net cash provided by operating activities increased to $12.17 million for the nine months, up from $11.83 million in the prior-year period.
• The Supplier Partnering Agreement with Abbott Laboratories was extended through December 31, 2027, reducing immediate customer concentration risk.
• Anticipated advanced manufacturing investment tax credits are expected to favorably impact the full-year fiscal 2026 tax rate by $700,000 to $1,000,000.
• Accelerated deductions of previously unamortized research and development expenses are expected to reduce cash taxes for fiscal 2026 by approximately $1,100,000.

Negatives

• Gross margin percentage decreased to 79% for both the quarter and nine-month periods, down from 84% and 85% respectively, due to a less profitable product mix and increased distributor sales.
• Nine-month net income decreased 8% year-over-year to $10.27 million.
• Interest income decreased 3% for the quarter due to a smaller marketable securities portfolio.
• Other income significantly decreased for both the quarter and nine-month periods, primarily due to a non-recurring gain from reclaiming precious metals in the prior year.
• The effective tax rate increased to 20% for the quarter and 19% for the nine months, primarily due to unfavorable non-cash impacts of tax law changes.
• Cash and cash equivalents decreased by $4.63 million during the first nine months of fiscal 2026.
• Fixed asset purchases significantly increased to $2.18 million for the nine months, up from $1.16 million in the prior-year period, consuming more cash.

Risks

• Reliance on several large customers for a significant percentage of revenue.
• Uncertainties related to the economic environments in the industries served.
• Uncertainties related to future sales and revenues.
• Risks and uncertainties related to tariffs, customs, duties, and other trade barriers.
• Risks and uncertainties related to future stock repurchases and dividend payments.
• Changes in state regulatory requirements, such as mandated paid leave in Minnesota effective January 1, 2026, may materially and adversely affect financial condition, results of operations, and cash flows by increasing employment costs and risk of employee absences.
• Inability to renew customer agreements, including the Supplier Partnering Agreement with Abbott Laboratories, or renew them under unfavorable terms, could have a significant adverse impact on revenue or profitability.

Future Outlook

The company expects a full-year tax rate of 16% to 17% for fiscal 2026, benefiting from anticipated advanced manufacturing investment tax credits of $700,000 to $1,000,000 and accelerated deductions of previously unamortized research and development expenses, which are projected to reduce cash taxes by approximately $1,100,000. Future dividends will remain subject to Board approval, operating results, cash and marketable security balances, and future cash requirements.

Management Comments

• "The increase in product sales was due to increases in both defense and non-defense sales, as well as increases in sales through both direct and distributor channels."
• "The increase in contract research and development revenue was due to new research and development contracts."
• "The decrease in gross margin percentage was due to a less profitable product mix and increased distributor sales for the quarter."
• "The decrease in research and development expense was due to the completion of some of our wafer-level chip scale packaging activities and reassignment of some research and development resources to manufacturing."
• "The decrease in selling, general, and administrative expenses was primarily due to the timing of marketing activities and reassignment of some selling, general and administrative resources to manufacturing and new product development."
• "We currently expect a full-year tax rate of 16% to 17% for fiscal 2026. This expectation includes the unfavorable impact of tax law changes and the favorable impact of $700,000 to $1,000,000 in anticipated advanced manufacturing investment tax credits."
• "We expect accelerated deductions of previously unamortized research and development expenses to reduce our cash taxes for the full fiscal year ending March 31, 2026 by approximately $1,100,000."
• "All future dividends will be subject to Board approval and subject to the company's results of operations, cash and marketable security balances, estimates of future cash requirements, and other factors the Board may deem relevant."

Industry Context

NVE Corporation operates in the specialized field of spintronics, a nanotechnology focused on electron spin for data acquisition, storage, and transmission. The company's performance, particularly its growth in product sales across defense and non-defense sectors, suggests continued demand for high-performance spintronic sensors and couplers. The increase in contract R&D revenue indicates ongoing innovation and potential for new applications within this niche, high-tech industry. However, the decline in gross margin due to product mix and increased distributor sales suggests competitive pressures or strategic shifts in sales channels that could impact profitability within the industry.

Corporate Governance

Legal Proceedings

• No material pending or threatened legal proceedings or other proceedings contemplated by governmental authorities are expected to have a material adverse impact on future results of operation and financial condition.

Stakeholder Impact

• Shareholders: Continued cash dividends ($1.00 per share declared for the quarter, another $1.00 declared post-period), existing stock repurchase program authorization ($3,520,369 remaining).
• Employees: Increased employment costs and potential risk of absences due to new Minnesota state legislation mandating paid leave effective January 1, 2026. Participation in 401(k) savings plan with matching contributions.
• Customers: Strong product sales growth and new R&D contracts indicate continued demand and engagement. Extension of Abbott Laboratories agreement provides stability.
• Creditors: Healthy operating cash flow and significant marketable securities portfolio ($43.59 million) provide strong liquidity.

Next Steps

• Payment of $1.00 per share cash dividend on February 27, 2026.
• Adoption of ASU 2023-09 for fiscal 2026, resulting in income tax disclosure changes in the next Annual Report on Form 10-K.
• Adoption of ASU 2025-05 for fiscal 2027, resulting in disclosure changes.
• Adoption of ASU 2024-03 for fiscal 2028 (annual) and fiscal 2029 (interim), resulting in disclosure changes.
• Continued monitoring of market conditions for potential stock repurchases under the existing authorization.

Key Dates

Recommendation

While NVE Corporation demonstrated strong quarterly revenue and net income growth, driven by increased product sales and R&D contracts, the nine-month performance shows a decline in net income and gross margin compression. The extension of the Abbott Laboratories agreement is a positive for revenue stability, and expense management is effective. However, the decrease in cash and cash equivalents, coupled with new state regulatory risks impacting employment costs, presents a mixed outlook. The company's consistent dividend payout and remaining stock repurchase authorization provide shareholder value, but the overall financial picture suggests a 'hold' position as investors await clearer trends in profitability and margin recovery.

Keywords

spintronics, nanotechnology, sensors, couplers, semiconductors, Q3 earnings, SEC 10-Q, financial results, dividends, marketable securities, research and development, corporate governance, risk factors, Abbott Laboratories